533. Protocol for and Efficacy of Monoclonal Antibody (mAb) Treatment of SARS-CoV-2 at a VA Medical Center

BACKGROUND: Bamlanivimab and casirivimab/imdevimab were the first monoclonal antibodies (mAb) developed against SARS-CoV-2 and proved beneficial early in the course of infection. However, real-world administration of these therapies presents logistical challenges. We present our experience implement...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Phuong Khanh, Dieringer, Thomas D, Greeley, Adela, Kun, Suny, Calub, Feliza, Pham, My-Phuong, Graber, Christopher J, Goetz, Matthew B, Ikuta, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644256/
http://dx.doi.org/10.1093/ofid/ofab466.732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644256/
http://dx.doi.org/10.1093/ofid/ofab466.732

Ejemplares similares